Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

NCT05569772 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2026-05-05

No results posted yet for this study

Summary

Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.

Conditions

  • Glucose Intolerance After a Recent History of Gestational Diabetes

Interventions

DRUG

Semaglutide Pen Injector

maintenance dose of 1mg SC once weekly

DRUG

Semaglutide placebo

maintenance dose of 1mg SC once weekly

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER
  • Universitair Ziekenhuis Brussel

    collaborator OTHER
  • General Hospital Groeninge

    collaborator OTHER
  • Onze Lieve Vrouw Hospital

    collaborator OTHER
  • Jessa Hospital

    collaborator OTHER
  • Ziekenhuis Netwerk Antwerpen (ZNA)

    collaborator OTHER
  • Vitaz

    collaborator OTHER
  • Centre Hospitalier Universitaire de Liege

    collaborator OTHER
  • Erasme University Hospital

    collaborator OTHER
  • Centre Hospitalier Mouscron

    collaborator UNKNOWN
  • Jan Yperman Ziekenhuis

    collaborator OTHER
  • AZ Turnhout

    collaborator OTHER
  • AZ Sint-Lucas Brugge

    collaborator OTHER
  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-14
Primary Completion
2029-06-30
Completion
2029-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569772 on ClinicalTrials.gov